Abstract:Background: The approval of immune checkpoint therapies has revolutionized cancer treatment and established immuno-therapy as an additional treatment option. However, while anti-PD-(L)1 therapies have demonstrated durable responses, only a small subset of patients respond. One mechanism of tumor escape is via the release of immunosuppressive metabolites such as adenosine. CD73, an extracellular enzyme expressed on immune cells and some tumors, catalyzes the conversion of AMP to adenosine, the rate limiting step in adenosine production. As a strategy to improve response rates we developed a first in class CD73/PD-1 targeting DFC, comprised of a multivalent conjugate of a small molecule CD73 inhibitor stably linked to a proprietary human IgG1 Fc-fusion with a PD-1 inhibitor peptide. This multispecific DFC has the potential for differentiation and increased therapeutic potency compared to approved PD-(L)1 inhibitors. Methods: Binding of CD73/PD-1-001 to biotinylated hPD-1 was determined using ELISA and to human CD8+ T cells by flow cytometry. CD73 inhibition was measured in cell-free and cell-based assays. Efficacy was determined in a humanized mouse model optimized for PD-1 activity against a transgenic MC-38 colon cell line expressing hPD-L1 (Genoway, France). Tumor volumes were recorded and statistical analysis was conducted by t-test (Mann-Whitney) or two-way ANOVA. Results: In vitro, CD73/PD-1-001 demonstrated potent activity against both checkpoint targets. CD73/PD-1-001 bound to hPD-1 with an IC50 of < 1 nM and demonstrated functional inhibition of CD73 with an EC50 of 70% at dose concentrations of 3 mg/kg or greater (p≤0.01). However, at the lowest test concentration of 1 mg/kg, only CD73/PD-1-001 retained significant potency with a TGI of 56.0 % (p ≤ 0.05). Tumor reduction in the 1 mg/kg PD-1-001 group did not reach statistical significance (36.5%, p > 0.05). Conclusions: This work demonstrates that a multispecific CD73/PD-1 targeting DFC, is a potent inhibitor of tumor growth in a humanized mouse model. Furthermore, CD73/PD-1-001 was more potent than PD-1 monotherapy, demonstrating the therapeutic benefit of targeting two important checkpoints with a single agent molecule. Collectively, preclinical testing of a CD73/PD-1 DFC has validated the benefits of targeting the PD-(L)1 axis in combination with adenosine suppression, resulting in improved anti-tumor effects. Citation Format: James Levin, Simon Döhrmann, Nicholas Dedeic, Amanda Almaguer, Doug Zuill, Elizabeth Abelovski, Jason N. Cole, Jeffrey B. Locke, Joanne Fortier, Qiping Zhao, Maria Hernandez, Karin Amundson, Madison Moniz, Hongyuan Chen, Dhanya Panickar, Thanh Lam, Tom Brady, Allen Borchardt, Grayson Hough, Leslie W. Tari. Discovery of a multispecific CD73/PD-1 targeting drug Fc-conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2728.

Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

Preparation and characterization of a novel monoclonal antibody against human PD-1

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1

Residue Specific Binding Mechanisms of PD-1 to Its Monoclonal Antibodies by Computational Alanine Scanning

Identification of a Monoclonal Antibody That Targets PD-1 in a Manner Requiring PD-1 Asn58 Glycosylation

Structure-guided Design Fine-Tunes Pharmacokinetics, Tolerability, and Antitumor Profile of Multispecific Frizzled Antibodies

A Fully Human Monoclonal Antibody Targeting PD-L1 with Potent Anti-Tumor Activity.

Structural Basis of the Therapeutic Anti-Pd-l1 Antibody Atezolizumab.

Residue-specific binding mechanisms of PD-L1 to its monoclonal antibodies by computational alanine scanning

Selection of a PD-1 blocking antibody from a novel fully human phage display library

A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody

Abstract 2728: Discovery of a multispecific CD73/PD-1 targeting drug Fc-conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model

Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody

Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.

Structural Basis of a Novel PD-L1 Nanobody for Immune Checkpoint Blockade

Polymeric PD1/PDL1 Bispecific Antibody Enhances Immune Checkpoint Blockade Therapy

Abstract 2963: CDX-585, a novel bispecific antibody targeting PD-1 and ILT4

Understanding the Structural and Energetic Basis of PD-1 and Monoclonal Antibodies Bound to PD-L1: A Molecular Modeling Perspective.

Structure- and machine learning-guided engineering demonstrate that a non-canonical disulfide in an anti-PD-1 rabbit antibody does not impede antibody developability

895 Discovery of a safer 4–1BB agonist by targeting a membrane-proximal epitope combined with bispecific-mediated cross-bridging